부산대학교 도서관

Currently, cancer multigene panel testing is available using next generation sequencer (NGS), which facilitates the carrying out of genomic medicine in clinical practice. This testing has two objectives, one is companion diagnostics and another is genome profiling. In Japan, two cancer gene panel tests were approved in June 2019 for genome profiling, OncoGuideTM NCC oncopanel, and FoundationOne® CDx cancer genome profiles, and are being used in approximately 170 medical institutions at present in Japan. Before the report is returned to the treating physicians, actionable gene aberrations and possible treatments are discussed at the molecular tumor board meeting by a multidisciplinary team, a so-called “expert panel”.Those two multigene panels use formalin-fixed paraffin-embedded (FFPE) tissue blocks to analyze. The quality of extracted DNA is associated with the success rate of analyzing DNA sequencing. To improve the success rate of the DNA sequencing, the concentration of formaldehyde, fixation time, and storage period of FFPE are very important. The strage period of FFPE samples is recommended to be within 3 years.It was previously reported that around 10% of patients received molecular-targeted therapy according to their gene aberrations, and 70% of them could receive investigational drugs after enrollment into a clinical trial. Genomic medicine will improve the treatment efficacy in patients with malignancies and promote drug development in the future.